ID
41687
Descrizione
The primary objective of this study was to demonstrate bioequivalence between eltrombopag oral film-coated tablets manufactured at Research and Development (R&D) and Commercial sites. The subject participants each went through two dosing periods (Period 1 and Period 2), during each of which they received a single dose of eltrombopag. The dosing periods were separated by a washout of at least 10 days. For each period, subjects had to perform a visit on the day before and one on the day of the administration of the drug. Furthermore, the protocol-defined visits included a screening visit and a follow-up visit. Study ID: 105122 Clinical Study ID: 105122 Study Title: Phase I Bioequivalence Study for SB 497115 GR Phase II and Phase III Tablets Sponsor: GlaxoSmithKline Phase: phase 1 Study Recruitment Status: Completed Generic Name: Eltrombopag Study Indication: Thrombocytopenia This form has to be filled out at the at the P1 D-1, P2 D-1, P1 D1 and P2 D1 Visits.
Keywords
versioni (1)
- 17/12/20 17/12/20 -
Titolare del copyright
GlaxoSmithKline
Caricato su
17 dicembre 2020
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
GSK Eltrombopag Thrombocytopenia, Clinical Study ID: 105122
Similar models
Meal
- StudyEvent: ODM
C0178602 (UMLS CUI-2)
C0011008 (UMLS CUI-3)
C0040223 (UMLS CUI-4)
C0178602 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0040223 (UMLS CUI [2,3])
C0439564 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C1998602 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2,1])
C1998602 (UMLS CUI [2,2])
C1998602 (UMLS CUI [1,2])
C1522314 (UMLS CUI [2,1])
C1998602 (UMLS CUI [2,2])
C0205197 (UMLS CUI [1,2])